1. World Health Organization. Renal cell tumours. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 32-42.
2. Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 2008;32:377-82.
4. Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol 2009;33:241-7.
5. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75-83.
8. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 2018;23:313-26.e5.
12. World Health Organization. Papillary renal cell carcinoma. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 47-9.
14. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-44.
15. Rizzo M, Calio A, Brunelli M, Pezzicoli G, Ganini C, Martignoni G, et al. Clinico-pathological implications of the 2022 WHO renal cell carcinoma classification. Cancer Treat Rev 2023;116:102558.
16. Moch H, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2022;82:458-68.
17. Alaghehbandan R, Campbell SC, McKenney JK. Evolution in the pathologic classification of renal neoplasia. Urol Clin North Am 2023;50:181-9.
19. Hes O, Condom Mundo E, Peckova K, Lopez JI, Martinek P, Vanecek T, et al. Biphasic squamoid alveolar renal cell carcinoma: a distinctive subtype of papillary renal cell carcinoma? Am J Surg Pathol 2016;40:664-75.
20. Skenderi F, Ulamec M, Vanecek T, Martinek P, Alaghehbandan R, Foix MP, et al. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol 2017;27:48-56.
21. Park BH, Ro JY, Park WS, Jee KJ, Kim K, Gong G, et al. Oncocytic papillary renal cell carcinoma with inverted nuclear pattern: distinct subtype with an indolent clinical course. Pathol Int 2009;59:137-46.
22. Kunju LP, Wojno K, Wolf JS Jr, Cheng L, Shah RB. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol 2008;39:96-101.
23. Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, et al. Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations. Am J Surg Pathol 2020;44:901-16.
24. Jung SJ, Chung JI, Park SH, Ayala AG, Ro JY. Thyroid follicular carcinoma-like tumor of kidney: a case report with morphologic, immunohistochemical, and genetic analysis. Am J Surg Pathol 2006;30:411-5.
27. World Health Organization. Oncocytoma of the kidney. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 50-8.
29. Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T. Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 2020;44:943-54.
31. World Health Organization. Eosinophilic solid and cystic renal cell carcinoma. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 69-70.
32. Palsgrove DN, Li Y, Pratilas CA, Lin MT, Pallavajjalla A, Gocke C, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol 2018;42:1166-81.
35. Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol 2017;41:1299-308.
36. Tsao MS, Yatabe Y. Old soldiers never die: is there still a role for immunohistochemistry in the era of next-generation sequencing panel testing? J Thorac Oncol 2019;14:2035-8.
37. Andrici J, Gill AJ, Hornick JL. Next generation immunohistochemistry: emerging substitutes to genetic testing? Semin Diagn Pathol 2018;35:161-9.
38. World Health Organization. TFE3-rearranged renal cell carcinomas. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 72-3.
40. Rao Q, Shen Q, Xia QY, Wang ZY, Liu B, Shi SS, et al. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity. Am J Surg Pathol 2015;39:1181-96.
43. Sukov WR, Hodge JC, Lohse CM, Leibovich BC, Thompson RH, Pearce KE, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol 2012;36:663-70.
44. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007;31:1149-60.
45. World Health Organization. TFEB-altered renal cell carcinomas. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 74-5.
47. Xia QY, Wang XT, Fang R, Wang Z, Zhao M, Chen H, et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol 2020;44:477-89.
48. Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol 2016;40:1484-95.
50. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RTPCR, and DNA PCR. Am J Surg Pathol 2005;29:230-40.
51. World Health Organization. ELOC (formerly TCEB1)-mutated renal cell carcinoma. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 76-7.
54. Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol 2018;42:279-92.
55. Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol 2016;40:1457-72.
56. Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol 2020;44:98-110.
60. World Health Organization. Fumarate hydratase-deficient renal cell carcinoma. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 78-9.
61. Gardie B, Remenieras A, Kattygnarath D, Bombled J, Lefevre S, Perrier-Trudova V, et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet 2011;48:226-34.
63. Sun G, Zhang X, Liang J, Pan X, Zhu S, Liu Z, et al. Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res 2021;27:1734-43.
64. Gill AJ, Hes O, Papathomas T, Sedivcova M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 2014;38:1588-602.
66. Smith NE, Deyrup AT, Marino-Enriquez A, Fletcher JA, Bridge JA, Illei PB, et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am J Surg Pathol 2014;38:858-63.
69. World Health Organization. ALK-rearranged renal cell carcinomas. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 82-3.
70. Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol 2018;74:124-8.
73. World Health Organization. SMARCB1-deficient renal medullary carcinoma. In: Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. p. 84-6.
75. World Health Organization. Urinary system and male genital tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2022.
76. Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 2014;21:394-410.
77. Agaimy A, Amin MB, Gill AJ, Popp B, Reis A, Berney DM, et al. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Hum Pathol 2018;77:139-46.
78. Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B, et al. Rhabdoid and undifferentiated phenotype in renal cell carcinoma: analysis of 32 cases indicating a distinctive common pathway of dedifferentiation frequently associated with SWI/SNF complex deficiency. Am J Surg Pathol 2017;41:253-62.
80. Ryan A, Tawagi K, VanderVeen N, Matrana M, Vasquez R. Combination therapy with bortezomib in renal medullary carcinoma: a case series. Clin Genitourin Cancer 2021;19:e395-400.